Skip to main content

Advertisement

Table 1 (abstract P004). Patient characteristics

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

  Patients with pulmonary complications Patients without pulmonary complications P-value
Patient number 65 849  
Observation years total (IQR) 7.6 (4.3-10.2) 5.1 (2.4-9.1) 0.002
Age diagnosis SJIA (IQR) 3.7 (2.3-5.6) 5.3 (2.9-9.3) <0.001
Patients with non-pulmonary AE/ESI 56 (86.2%) 287 (33.8%) <0.001
Synthetic DMARDs ever 52 (80.0%) 690 (81.3%) 0.745
Anti-TNF ever 25 (38.5%) 307 (36.2%) 0.691
Anti-IL1 ever 29 (44.6%) 332 (39.1%) 0.430
Tocilizumab ever 36 (55.4%) 345 (40.6%) 0.026
Rituximab ever 20 (30.8%) 49 (5.8%) <0.001
  1. Values are the number of patients, unless stated otherwise. Continuous variables are analysed by a Mann-Witney-U test, asymp. Sig. (2-tailed). For dichotomous variables Fisher’s exact sig. (2-sided) is used